Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Docetaxel | |
| Synonyms |
|
|
| Definitions |
A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1526 |
|
| Accepted_Therapeutic_Use_For |
Breast cancer; Esophageal cancer; Gastric cancer; Head/Neck cancers; Locally Advanced or Metastatic Non small-cell lung cancer; Ovarian cancer; Metastatic Prostate cancer
|
|
| ALT_DEFINITION |
A drug used together with other drugs to treat certain types of breast cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer. It is also being studied in the treatment of other types of cancer. Docetaxel is a type of mitotic inhibitor.
|
|
| CAS_Registry |
148408-66-6
|
|
| CHEBI_ID |
CHEBI:59809
|
|
| Chemical_Formula |
C43H53NO14.3H2O
|
|
| code |
C1526
|
|
| Contributing_Source |
CTRP FDA PCDC
|
|
| definition |
A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)
|
|
| Display_Name |
Docetaxel
|
|
| FDA_UNII_Code |
15H5577CQD
|
|
| Has_Target |
http://purl.obolibrary.org/obo/NCIT_C20450 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C179531 http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C179478 |
|
| Is_Value_For_GDC_Property | ||
| label |
Docetaxel
|
|
| Legacy Concept Name |
Docetaxel
|
|
| Maps_To |
Docetaxel
|
|
| NCI_Drug_Dictionary_ID |
41657
|
|
| NSC Number |
628503
|
|
| PDQ_Closed_Trial_Search_ID |
41657
|
|
| PDQ_Open_Trial_Search_ID |
41657
|
|
| Preferred_Name |
Docetaxel
|
|
| prefixIRI |
NCIT:C1526
|
|
| prefLabel |
Docetaxel
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C0246415
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |